$0.75 EPS Expected for Haemonetics Co. (NYSE:HAE) This Quarter

Wall Street analysts expect that Haemonetics Co. (NYSE:HAE) will announce $0.75 earnings per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Haemonetics’ earnings. The highest EPS estimate is $0.82 and the lowest is $0.70. Haemonetics reported earnings per share of $0.46 during the same quarter last year, which would indicate a positive year over year growth rate of 63%. The company is scheduled to issue its next quarterly earnings report on Tuesday, August 3rd.

On average, analysts expect that Haemonetics will report full-year earnings of $3.52 per share for the current fiscal year, with EPS estimates ranging from $3.42 to $3.65. For the next fiscal year, analysts forecast that the firm will report earnings of $3.92 per share, with EPS estimates ranging from $3.25 to $4.85. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Haemonetics.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, May 13th. The medical instruments supplier reported $0.46 EPS for the quarter, missing analysts’ consensus estimates of $0.67 by ($0.21). The company had revenue of $225.00 million for the quarter, compared to analysts’ expectations of $223.92 million. Haemonetics had a return on equity of 22.85% and a net margin of 11.76%. The firm’s quarterly revenue was down 5.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.69 EPS.

A number of research firms recently commented on HAE. Jefferies Financial Group decreased their price objective on shares of Haemonetics from $105.00 to $85.00 and set a “buy” rating on the stock in a report on Friday. Barrington Research reduced their price target on shares of Haemonetics from $91.00 to $71.00 and set an “outperform” rating on the stock in a report on Friday. Raymond James upped their price target on shares of Haemonetics from $145.00 to $155.00 and gave the company an “outperform” rating in a report on Friday, February 12th. Morgan Stanley reduced their price target on shares of Haemonetics from $83.00 to $75.00 and set an “equal weight” rating on the stock in a report on Friday. Finally, JMP Securities reduced their price target on shares of Haemonetics from $110.00 to $90.00 and set an “outperform” rating on the stock in a report on Friday. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $101.29.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Van ECK Associates Corp purchased a new position in shares of Haemonetics during the first quarter valued at approximately $28,000. Meeder Asset Management Inc. lifted its stake in shares of Haemonetics by 7,350.0% during the first quarter. Meeder Asset Management Inc. now owns 298 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 294 shares during the period. Altshuler Shaham Ltd acquired a new position in Haemonetics during the first quarter worth approximately $35,000. Berman Capital Advisors LLC acquired a new position in Haemonetics during the fourth quarter worth approximately $47,000. Finally, IFP Advisors Inc increased its position in Haemonetics by 531.0% during the fourth quarter. IFP Advisors Inc now owns 530 shares of the medical instruments supplier’s stock worth $62,000 after purchasing an additional 446 shares during the last quarter. 96.22% of the stock is currently owned by institutional investors and hedge funds.

HAE stock traded up $4.19 during trading on Tuesday, reaching $56.00. 2,091,051 shares of the company were exchanged, compared to its average volume of 719,303. The company has a market cap of $2.85 billion, a P/E ratio of 27.05, a PEG ratio of 5.17 and a beta of 0.56. Haemonetics has a 52-week low of $49.26 and a 52-week high of $142.11. The stock’s 50 day moving average price is $89.99 and its 200 day moving average price is $111.81. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.34 and a current ratio of 2.25.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

See Also: What does an inverted yield curve signify?

Get a free copy of the Zacks research report on Haemonetics (HAE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.